Schwartz Jeffrey Lawrence
CIK: 0001702957
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RPID Presents at Small-Cap Virtual Conference. Rapid Micro Biosystems presented at a small‑cap virtual conference, sharing updates on its product pipeline and business strategy. The event offered investors a chance to hear directly from management about recent progress and future plans. The presentation follows the company’s recent trading activity, with an RSI of 31.3 and support near $1.66.
Transaction History
| KMTS | ▲ Buy | Grant | 7,217 | — | 9/9/2026 | View on chart |
| KMTS | ▼ Sell | Open Market | 3,890 | $98K | 9/8/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 10,909 | — | 9/4/2025 | View on chart |
| RPID | ▲ Buy | Grant | 14,300 | $0 | 5/23/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target
BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target. BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.